Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study

Review

(2183) Views  (688) Full article downloads

Authors: JP Baguet, R Asmar, P Valensi, S Nisse-Durgeat, JM Mallion

Published Date January 2009 Volume 2009:5 Pages 175 - 183

DOI: http://dx.doi.org/10.2147/VHRM.S3409

JP Baguet¹, R Asmar², P Valensi³, S Nisse-Durgeat⁴, JM Mallion¹

¹Clinique de Cardiologie, CHU de Grenoble, Grenoble, France; ²Institut CardioVasculaire, Paris, France; ³Service d’Endocrinologie-Diabétologie-Nutrition, CHU Jean Verdier, AP-HP, Bondy, France; ⁴Laboratoires Takeda, Puteaux, France

Abstract: In hypertension and diabetes, early structural changes of the arterial wall precede or support atherosclerosis. There is evidence that some antihypertensive drugs exert an antiatherosclerotic effect. Over 36 months, we investigated the effect of candesartan cilexetil (CC) on the common carotid intima-media thickness (IMT) vs amlodipine besylate (AML) in patients with type 2 diabetes and mild to moderate essential hypertension. After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12.5 mg if necessary. No significant differences were observed between the two groups for change in IMT at M12 (−0.001 vs −0.027 mm/year for CC and AML respectively, p = 0.425), at M24 (−0.033 vs −0.019 mm per year respectively, p = 0.442), and at the last visit (−0.016 vs −0.039 mm per year respectively, p = 0.549). Within the group, comparisons did not show a significant difference in changes in IMT from baseline to the three visits. At the last visit, IMT regression was observed in 52.2% of patients receiving CC and in 51.3% of those receiving AML (p = 0.908). The augmentation in carotid lumen diameter from baseline was statistically greater in the AML group at the last visit (p = 0.034). BP variations during the study were similar in the two groups. The results of this study show that CC and AML treatments may alter identically the natural progression of carotid IMT in hypertensive type 2 diabetic patients.

Keywords: hypertension, diabetes, carotid, intima-media thickness, candesartan, amlodipine

Other articles by Professor Jean-Philippe Baguet